Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma

Abstract Glioblastoma multiforme (GBM) is the most prevalent, treatment-resistant, and fatal form of brain malignancy. It is characterized by genetic heterogeneity, and an infiltrative nature, and GBM treatment is highly challenging. Despite multimodal therapies, clinicians lack efficient prognostic...

Full description

Saved in:
Bibliographic Details
Main Authors: Elham Ali, Marwa Adel Ahmed, May A. Shawki, Lobna R. Ezz El Arab, Mohamed K. Khalifa, Menha Swellam
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-83800-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594789329010688
author Elham Ali
Marwa Adel Ahmed
May A. Shawki
Lobna R. Ezz El Arab
Mohamed K. Khalifa
Menha Swellam
author_facet Elham Ali
Marwa Adel Ahmed
May A. Shawki
Lobna R. Ezz El Arab
Mohamed K. Khalifa
Menha Swellam
author_sort Elham Ali
collection DOAJ
description Abstract Glioblastoma multiforme (GBM) is the most prevalent, treatment-resistant, and fatal form of brain malignancy. It is characterized by genetic heterogeneity, and an infiltrative nature, and GBM treatment is highly challenging. Despite multimodal therapies, clinicians lack efficient prognostic and predictive markers. Therefore, new insights into GBM management are urgently needed to increase the chance of therapeutic success. Circulating miRNAs (miRs) are important regulators of cancer progression and are potentially useful for GBM diagnosis and treatment. This study investigated how miR-29a, miR-106a, and miR-200a affect the prognosis of GBM patients. This study was conducted on 25 GBM patients and 20 healthy volunteers as a control group. The expression levels of target miRs were analyzed pre- and post-treatment using qRT-PCR and evaluated in relation to both clinical GBM criteria and the patient’s survival modes. The diagnostic efficacy of target miRs was assessed using the receiver operating characteristic (ROC) curve. MiRs levels showed significant differences among the enrolled participants. All investigated miRs were significantly elevated in GBM patients with non-frontal lesions. Only miR-200a showed a significant difference in GBM patients older than 60 years with a tumor size ≥ 5 mm. Regarding miR-106a, a significant difference was detected based on the surgical strategy and use of an Eastern Cooperative Oncology Group (ECOG) performance status equal to 2. For miR-29a, a significant upregulation was detected according to the surgical strategy. All post-treatment miRs levels in GBM patients were significantly downregulated. In conclusion, circulating miRs revealed a significant role in predicting GBM patient treatment outcomes providing valuable insights for personalized therapeutic strategies.
format Article
id doaj-art-b91bae3f20484d2b83aaafaa8f2520a2
institution Kabale University
issn 2045-2322
language English
publishDate 2025-01-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-b91bae3f20484d2b83aaafaa8f2520a22025-01-19T12:21:00ZengNature PortfolioScientific Reports2045-23222025-01-0115111410.1038/s41598-024-83800-xExpression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastomaElham Ali0Marwa Adel Ahmed1May A. Shawki2Lobna R. Ezz El Arab3Mohamed K. Khalifa4Menha Swellam5Molecular Biology, Zoology and Entomology Department, Faculty of Science (for Girls), Al-Azhar UniversityClinical Pharmacy Department, Faculty of Pharmacy, Ain Shams UniversityClinical Pharmacy Department, Faculty of Pharmacy, Ain Shams UniversityClinical Oncology Department, Faculty of Medicine, Ain Shams UniversityCSO at OmicsenseBiochemistry Department, Biotechnology Research Institute, National Research CentreAbstract Glioblastoma multiforme (GBM) is the most prevalent, treatment-resistant, and fatal form of brain malignancy. It is characterized by genetic heterogeneity, and an infiltrative nature, and GBM treatment is highly challenging. Despite multimodal therapies, clinicians lack efficient prognostic and predictive markers. Therefore, new insights into GBM management are urgently needed to increase the chance of therapeutic success. Circulating miRNAs (miRs) are important regulators of cancer progression and are potentially useful for GBM diagnosis and treatment. This study investigated how miR-29a, miR-106a, and miR-200a affect the prognosis of GBM patients. This study was conducted on 25 GBM patients and 20 healthy volunteers as a control group. The expression levels of target miRs were analyzed pre- and post-treatment using qRT-PCR and evaluated in relation to both clinical GBM criteria and the patient’s survival modes. The diagnostic efficacy of target miRs was assessed using the receiver operating characteristic (ROC) curve. MiRs levels showed significant differences among the enrolled participants. All investigated miRs were significantly elevated in GBM patients with non-frontal lesions. Only miR-200a showed a significant difference in GBM patients older than 60 years with a tumor size ≥ 5 mm. Regarding miR-106a, a significant difference was detected based on the surgical strategy and use of an Eastern Cooperative Oncology Group (ECOG) performance status equal to 2. For miR-29a, a significant upregulation was detected according to the surgical strategy. All post-treatment miRs levels in GBM patients were significantly downregulated. In conclusion, circulating miRs revealed a significant role in predicting GBM patient treatment outcomes providing valuable insights for personalized therapeutic strategies.https://doi.org/10.1038/s41598-024-83800-xGlioblastomamiR-29amiR-106amiR-200aBiomarkersIn silico analysis
spellingShingle Elham Ali
Marwa Adel Ahmed
May A. Shawki
Lobna R. Ezz El Arab
Mohamed K. Khalifa
Menha Swellam
Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
Scientific Reports
Glioblastoma
miR-29a
miR-106a
miR-200a
Biomarkers
In silico analysis
title Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
title_full Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
title_fullStr Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
title_full_unstemmed Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
title_short Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma
title_sort expression of some circulating micrornas as predictive biomarkers for prognosis and treatment response in glioblastoma
topic Glioblastoma
miR-29a
miR-106a
miR-200a
Biomarkers
In silico analysis
url https://doi.org/10.1038/s41598-024-83800-x
work_keys_str_mv AT elhamali expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma
AT marwaadelahmed expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma
AT mayashawki expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma
AT lobnarezzelarab expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma
AT mohamedkkhalifa expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma
AT menhaswellam expressionofsomecirculatingmicrornasaspredictivebiomarkersforprognosisandtreatmentresponseinglioblastoma